Early trial of PF-08046031 for advanced cancers ends early
NCT ID NCT06799533
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment options. The main goal was to check the drug's safety and side effects. The trial was terminated early, so its findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-08046031 (a drug given into the vein)
What this could lead to
If it works, this could point toward a new treatment option for advanced melanoma and other solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 11 participants, and it was terminated early, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val-de-marne, 94800, France
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], 08035, Spain
-
Karolinska Universitetssjukhuset Solna
Solna, Stockholms LÄN [se-01], 171 64, Sweden
-
Presbyterian/ St. Lukes Medical Center
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute at HealthONE - SCRI - PPDS
Denver, Colorado, 80218, United States
-
The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California, 90025, United States
-
The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate
Los Angeles, California, 90025, United States
-
The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only)
Santa Monica, California, 90404, United States
-
The Royal Marsden NHS Foundation Trust
Sutton, SM2 5PT, United Kingdom
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
UCSF Medical Center, Investigational Pharmacy
San Francisco, California, 94158, United States